Antifungal Activity of SCY-078 and Standard Antifungal Agents against 178 Clinical Isolates of Resistant and Susceptible Candida Species
Open accessAbstract
SCY-078 in vitro activity was determined for 178 isolates of resistant or susceptible Candida albicans , Candida dubliniensis , Candida glabrata , Candida krusei , Candida lusitaniae , and Candida parapsilosis , including 44 Candida isolates with known genotypic ( FKS1 or FKS2 mutations), phenotypic, or clinical resistance to echinocandins. Results were compared to those for anidulafungin, caspofungin, micafungin, fluconazole, and voriconazole. SCY-078 was shown to have excellent activity against both wild-type isolates and echinocandin- and azole-resistant isolates of Candida species.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
SCY-078 appears to be active against echinocandin-resistant and azole-resistant Candida strains, including C. auris.
“Importantly, SCY-078 appears to be active against echinocandin-resistant and azole-resistant Candida strains, including C. auris [111,112,113].”
From Treatment of Invasive Candidiasis: A Narrative Review (2018) · cites this paper as [111]
The citation lists haven’t been fetched yet
References 21 · Cited by 66
- Authors
- Schell, W. A., Jones, A. M., Borroto-Esoda, K., & Alexander, B. D.
- Affiliations
- Duke Medical Center (US)
- National Institutes of Health (US)
- Scynexis, Inc., Jersey City, New Jersey, USA
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2017-11
- Volume
- 61
- Issue
- 11
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- PMC
- PMC5655100
- OpenAlex
- W2745871749
- Cited by
- 66
- References
- 21
- Citations by year
- 2026: 5 · 2025: 2 · 2024: 8 · 2023: 5 · 2022: 9 · 2021: 15 · 2020: 8 · 2019: 10 · 2018: 4
- FWCI
- 4.63
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- Antimicrobial Agents and Chemotherapy (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Scynexis, Inc.
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Life Sciences › Agricultural and Biological Sciences › Ecology, Evolution, Behavior and Systematics › Fungal Plant Pathogen Control
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Yeasts and Rust Fungi Studies
- Keywords
- antifungal agents, Candida, echinocandin resistance, FKS1 mutations, Candida albicans, Candida glabrata, Candida parapsilosis, Candida dubliniensis, Candida krusei, Candida lusitaniae, anidulafungin, caspofungin, micafungin, fluconazole, voriconazole, azole resistance, antifungal susceptibility
- MeSH terms
- Anidulafungin, Antifungal Agents, Candida, Glycosides, Humans, Microbial Sensitivity Tests, Triterpenes, Drug Resistance, Fungal, Echinocandins, Voriconazole
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
